<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349167</url>
  </required_header>
  <id_info>
    <org_study_id>PR104-1001</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-0512034-01A</secondary_id>
    <secondary_id>PROACTA-PR-104-1001</secondary_id>
    <nct_id>NCT00349167</nct_id>
  </id_info>
  <brief_title>PR-104 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proacta, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Proacta, Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 in treating&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the safety and tolerability of PR-104 in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of PR-104 in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Characterize the pharmacokinetics of PR-104 and its alcohol metabolite in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess evidence of antitumor activity of this drug in these patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Examine metabolic changes in tumors of these patients using fludeoxyglucose F 18&#xD;
           positron emission tomography scanning.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, prospective, uncontrolled, dose-escalation study.&#xD;
&#xD;
      Patients receive PR-104 IV over 60 minutes on day 1. Treatment repeats every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PR-104 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Blood is collected at baseline and then periodically during study treatment for&#xD;
      pharmacokinetic and tumor marker studies. Patients undergo fludeoxyglucose F 18 positron&#xD;
      emission tomography scanning before beginning study treatment and after completion of course&#xD;
      2 to assess metabolic activity of the tumor.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>PR-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR-104</intervention_name>
    <arm_group_label>PR-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>PR-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>PR-104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor, meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Not amenable to standard therapy&#xD;
&#xD;
               -  Refractory to conventional therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/L (transfusion independent)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  PT/INR or aPTT ≤ 1.1 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No significant cardiac comorbidity including any of the following:&#xD;
&#xD;
               -  New York Heart Association class III-IV congenital heart failure&#xD;
&#xD;
               -  LVEF &lt; 40%&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Ventricular arrhythmias requiring drug therapy&#xD;
&#xD;
               -  Pacemaker or implanted defibrillator&#xD;
&#xD;
          -  No ongoing coagulopathy&#xD;
&#xD;
          -  No uncontrolled infection or infection requiring parenteral antibiotics&#xD;
&#xD;
          -  No other significant clinical disorder or laboratory finding that would preclude study&#xD;
             treatment&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No known positivity for hepatitis B surface antigen or hepatitis C with abnormal liver&#xD;
             tests&#xD;
&#xD;
          -  No known allergy to nonplatinum-containing alkylating agents&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 2 weeks since prior hormonal therapy (except for androgen-deprivation&#xD;
             therapy)&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 1 month since prior investigational drugs, therapies, or devices&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior high-dose chemotherapy, either myeloablative or nonmyeloablative&#xD;
             (mini-allogeneic transplant)&#xD;
&#xD;
          -  No more than 3 prior myelosuppressive chemotherapy regimens&#xD;
&#xD;
          -  Concurrent steroids allowed provided dose is stable for ≥ 2 weeks and clinical&#xD;
             condition is stable for 1 month&#xD;
&#xD;
               -  Nasal, opthalmologic, and topical glucocorticoid preparations allowed&#xD;
&#xD;
               -  Physiologic hormone replacement therapies allowed (i.e., oral replacement&#xD;
                  glucocorticoid therapy for adrenal insufficiency)&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic growth factors&#xD;
&#xD;
          -  No concurrent radiotherapy, including local palliative radiotherapy or systemic&#xD;
             radioisotopes&#xD;
&#xD;
               -  Radioisotopes for protocol specified positron emission tomography allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent chemotherapy, radiotherapy (including palliative local&#xD;
             radiotherapy), hormonal therapy (except for androgen-deprivation therapy), and/or&#xD;
             biological therapy (including immunotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.</citation>
    <PMID>20012293</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

